stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) EBITDA
Veracyte, Inc.'s EBITDA for fiscal 2025 was $75.9M, up 93.4% from $39.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $123.9M. Over the past ten years it has ranged from −$62.3M (fiscal 2021) to $75.9M (fiscal 2025) — the current reading is the highest in ten years. Veracyte, Inc. ranks 19th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $75.9M | 93.45% |
| FY2024 | $39.2M | — |
| FY2023 | −$59.1M | — |
| FY2022 | −$15.2M | — |
| FY2021 | −$62.3M | — |
| FY2020 | −$27.4M | — |
| FY2019 | −$10.9M | — |
| FY2018 | −$18.3M | — |
| FY2017 | −$22.2M | — |
| FY2016 | −$26.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $27.1M | (1.34%) |
| Mar 2026 | $27.5M | (34.37%) |
| Dec 2025 | $41.8M | 52.03% |
| Sep 2025 | $27.5M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SHC Sotera Health Company compare | $537.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. | $123.9M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| NEO NeoGenomics, Inc. compare | $17.5M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| WGS GeneDx Holdings Corp. compare | −$65.5M |
| GRAL GRAIL, Inc. compare | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement